News, reviews and podcasts from annual scientific meetings and symposiums around the world.
Highlights on a phase I of dual RAF/MEK inhibitor + FAK inhibitor in ovarian cancer…
Highlights on nivolumab plus ipilimumab vs EXTREME in 1st-line high-risk squamous cell carcinoma of the…
Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6
Highlights on adagrasib in patients with KRASG12C-mutated colorectal cancer: The KRYSTAL-1 study
Highlights on MFS analysis from combined treatments in high-risk advanced prostate cancer
Cleveland Clinic researchers from the USA, led by Federico Aucejo, MD, Director of the Liver…
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center, USA, has found…
The addition of immunotherapy to standard first-line treatment extends survival by eight months for patients…
A novel combination of well-known drugs prolongs survival in patients with hormone/castration-sensitive prostate cancer, according…
A new drug has shown promise in slowing the regrowth of tumours among some bowel…